Pharma & Bio
Technology
JointStem: Stalled in Korea but Rapidly Developed in the U.S.—Reasons Behind the Mixed Reactions
Regulatory authorities in South Korea and the United States have reached differing conclusions regarding “JointStem,” a stem cell therapy for degenerative knee osteoarthritis developed by NATURECELL C…
Lifestyle
'38 billion in Cash vs. 70 billion in Market Cap': Foreign Investors Buy EyeGene,Inc for 6th Consecutive Day... CEO Also Triples His Stake
Foreign investors are flocking to the new drug developer EyeGene,Inc(185490)as the perception that the company is undervalued continues to spread. Even as foreign investors sold off shares across the …
Lifestyle
Market Fluctuates; Daehwa Pharm, LabGenomics, and NeoImmuneTech Rise [K-Bio Pulse]
On the 7th, amid mixed trading in the South Korean stock market, pharmaceutical and biotech companies demonstrating clear earnings growth and solid momentum stood out. Departing from past trends that …
Lifestyle
Amid Mixed Market Conditions, DAE HWA PHARM CO., LTD., LabGenomics. Co., Ltd., and NeoImmuneTech, Inc. Rise [Bio Spotlight]
On the 7th, while the domestic stock market showed mixed trends, companies in the pharmaceutical and biotech sectors that demonstrated clear earnings growth and solid momentum stood out. Moving away f…
Lifestyle
D&D and Pfizer’s Momentum Remains Strong… The Key Lies in the Unannounced ‘MET-097o’
D&D Pharmatech’s stock price plummeted after Pfizer halted development of MET-224o, an oral obesity treatment candidate acquired through its acquisition of Metsera. However, it has been confirmed that…
Technology
“Phase 2b Isn’t Mandatory”… Will Kangstem Biotech’s Strategy of Speeding Through Clinical Trials Pay Off?
Bae Yo-han, Head of Clinical Development at Kangstem Biotech, is presenting at a briefing on the results of the Phase 2a clinical trial for “OSCA,” held on the 29th at the FKI Tower in Yeouido, Seoul.…
Technology
Exchange Rates Driven by CMO, Patent Cliffs by Biosimilars… Promising Sectors Amid the Recession
While the biotech industry is experiencing an overall slowdown in investment and a funding crunch, forecasts suggest that contract manufacturing organizations (CMOs) and contract development and manuf…
Technology
Novartis Moves Beyond Obesity to Lead in MASH… Why Is It Collecting Non-Invasive Data in Korea?
(Graphic: ChatGPT)
Danish pharmaceutical company Novo Nordisk has launched a large-scale real-world data study using medical records from approximately 10,000 patients in South Korea with metaboli…
Technology
[The Era of Oral Obesity Drugs, Part 2] Big Pharma vs. K-Bio: The Battle Grounds Are 'Price' and 'Formulation Innovation'
As the era of “oral” GLP-1 therapies officially begins in the global obesity treatment market, observers are suggesting that K-Bio companies may need to rethink their survival strategies. This is beca…
Lifestyle
Mezzion Pharma Co., Ltd. Simultaneously Improves Cysts and Kidney Function in ADPKD… “Moving Directly to Phase 2b Clinical Trials in Korea and the U.S.”
“When you examine the kidneys of mice with polycystic kidney disease, you can see large cysts. However, after administering Udenafil, a reduction in the size of these cysts was visible even to the nak…